US Bancorp DE Has $1.58 Million Stock Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• US Bancorp DE reduced its stake in Takeda Pharmaceutical Co. by 14.7% during the first quarter, holding 106,037 shares valued at approximately $1.58 million.
• Several institutional investors increased their holdings in Takeda, including JPMorgan Chase & Co., which raised its position by 94.5% during the fourth quarter.
• Takeda reported $0.52 earnings per share, exceeding analyst expectations and generating revenues of $7.45 billion for the quarter.

US Bancorp DE decreased its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 14.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,037 shares of the company's stock after selling 18,295 shares during the quarter. US Bancorp DE's holdings in Takeda Pharmaceutical were worth $1,577,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Soleus Capital Management L.P. boosted its position in shares of Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after acquiring an additional 680,000 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth about $6,760,000. BNP Paribas Financial Markets increased its position in shares of Takeda Pharmaceutical by 15,449.0% during the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after purchasing an additional 497,457 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $5,915,000. Finally, Northern Trust Corp lifted its stake in shares of Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after purchasing an additional 238,161 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

NYSE:TAK traded up $0.14 during mid-day trading on Wednesday, reaching $14.77. 1,313,718 shares of the stock were exchanged, compared to its average volume of 2,523,086. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company has a 50 day simple moving average of $14.80 and a 200-day simple moving average of $14.59. The stock has a market capitalization of $46.98 billion, a P/E ratio of 49.25 and a beta of 0.22. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.